New cord blood transplant recipe aims to beat tough blood cancers

NCT ID NCT05884333

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to improve survival and reduce side effects like graft-versus-host disease. About 54 participants will be enrolled at Memorial Sloan Kettering.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cord blood stem cells (double-unit graft) with conditioning chemotherapy (cyclophosphamide, fludarabine, thiotepa) and total body irradiation
What this could lead to
If successful, this could improve survival and reduce complications for adults with high-risk blood cancers who need a cord blood transplant.
What could go wrong
This is a small, single-center phase 2 study, so results may not apply broadly. Cord blood transplants carry risks like infection, graft failure, and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.